Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...

GlaxoSmithKline’s latest move to reinvigorate R&D is a collaboration with two of the biggest names in CRISPR research to develop new gene editing technologies and use them to identify drug targets. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...

TECHNOLOGY: Tool compounds; structural analyses Structural analysis of a peptide inhibitor bound to the cysteine-rich domain (CRD) of FZD7 could guide the development of small molecule FZD7 inhibitors, and the peptide could be used to...

INDICATION: Gastrointestinal Patient sample and mouse studies identified a BBC3 inhibitor that could help treat intestinal injury caused by topoisomerase inhibitors for cancer. In mice receiving the generic topoisomerase inhibitor irinotecan, BBC3 knockout increased survival...

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...